Group assessment
This PHI covers the named group; its members do not have separate PHI ratings.
https://dxm-atlas.org/en/interactions/salvinorin-a/
CompareKey points for this combination
Specific toxic synergy not established. Functional impairment and secondary physical hazards [17]
How well is this understood?
Mechanism confidence: medium
Confidence in the mechanism: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
How can the effects add up?
ⓘ
KOR — κ-opioid receptor
One type of opioid receptor.
κ and μ are labels for different types of opioid receptor.
Sources: KOR — κ-opioid receptor
- IUPHAR Pharmacology Education Project: Receptors · Live page accessed 2026-10-12; revision label unavailable
ⓘ
Cannabinoid-related effects / functional impairment and secondary physical hazards
Synergy
A combined effect that is stronger than expected from additivity.
Synergy is assessed by comparing the measured combined effect with the result predicted from the substances’ separate actions. The comparison uses a specified effect and a chosen model of additivity.
Sources: Synergy
- Roell, Reif and Motsinger-Reif: An Introduction to Terminology and Methodology of Chemical Synergy · Frontiers in Pharmacology 8:158 (20 April 2017); DOI 10.3389/fphar.2017.00158
Sources
Check the review’s wording
Specific toxic synergy not established; functional impairment and secondary physical hazards [17]
- [17] Human psychopharmacology and dose-effects of salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum · Open publication
What was studied for salvinorin A
Controlled studies of salvinorin A alone found relatively stable physiological measures under the studied conditions; they did not examine DXM. Salvinorin acts through a κ-opioid mechanism. Its pharmacology differs from the μ-opioid mechanism of fentanyl’s respiratory effects [17].